Hasil Pencarian  ::  Simpan CSV :: Kembali

"Trembesi merupakan tanaman kering yang hidup di daerah tropis yang berasal dari Amerika pusat yang menyebar luas hingga Venezuela dan Kolombia. Tanaman ini selain dimanfaatkan untuk mengurangi polusi udara dan menyerap air, biji dan daunnya dimanfaatkan oleh masyarakat sebagai obat. Sampai saat ini belum ada bukti apakah biji trembesi aman atau tidak untuk dikonsumsi. Oleh karena itulah peneliti merasa perlu untuk mengetahui toksisitas tanaman ini. Dalam penelitian ini, peneliti melakukan Uji toksisitas akut (LD50) untuk melihat efek toksisitas. Uji ini dilakukan dengan melihat kategori dosis manakah yang mampu membunuh 50% populasi sampel yang dicekoki trembesi. Setelah didapatkan, maka dapat ditentukan trembesi termasuk kategori dosis yang mana. Kategori dosis toksisitas yang dipakai pada penelitian ini adalah dosis moderately toxic. Pada penelitian ini organ yang diperiksa oleh peneliti adalah hati, karena hati merupakan organ yang berperan dalam menetralisasi zat-zat racun terutama yang masuk ketubuh melalui saluran pencernaan. Setelah dilakukan pencengkokan dengan ketiga rkstrak tersebut, tidak ada hewan coba yang mati. Kemudian setelah diamati sejak pemberian trembesi hingga hari ke-14. Tidak didapatkan mencit yang mati. Setelah itu, organ hati dari masing-masing hewan coba diambil untuk dibuat sediaan mikroskopiknya. Dari pemeriksaan, tidak ditemukan kelainan mikroskopik pada hati. Dapat disimpulkan bahwa trembesi terbukti tidak memiliki efek toksik pada hati mencit. LD50 untuk ketiga ekstrak tersebut adalah practically non-toxic.

---

Trembesi is plants that live in the tropics. This plant comes from central America who spread to Venezuela and Colombia. This plant is used in addition to reducing air pollution and absorb water, seeds and leaves are used by the community as a drug. Until now there has been no evidence whether the trembesi seeds is safe or not for consumption. That is why researchers find it necessary to know the toxicity of this plant.

In this study, researchers will use acute toxicity test (LD50) to see the effects of toxicity. This test is done by looking at what dose category are able to kill 50% of the sample population is fed a trembesi. Once obtained, trembesi can be categorized into six doses: supertoxic, extremely toxic, highly toxic, moderately toxic, slightly toxic, or Practically non-toxic. In this study the organ being examined by investigators is the heart, because the liver is the organ that plays a role in neutralizing toxic substances that enter through the gastrointestinal tract.

After the experiment, all mice survived. During the observation until the 14th day. There were no mice died. After that, the liver of each animal was taken for microscopic preparations made. From the examination, there was no microscopic abnormalities in liver Now, we can concluded that the trembesi didn’t show any toxic effects on the liver of mice. LD50 for the three extracts are Practically non-toxic."

"Kanker kolorektal merupakan keganasan ketiga terbanyak di Indonesia dengan 95% diantaranya adalah adenokarsinoma kolon. Saat ini, tatalaksana yang dapat diberikan berupa bedah reseksi atau laparoskopi masih terbatas khususnya pada kanker kolon stadiur akhir. Sehingga, masih diperlukan penelitian untuk menemukan terapi alternatif untuk mendukung tatalaksana yang ada. Salah satunya adalah kulit buah manggis yang dikatakan memiliki berbagai manfaat, termasuk antikanker. Ekstrak etanol kulit buah manggis (Garcinia mangostana l.) pada penelitian ini diuji efek sitotoksisitasnya terhadap sel adenokarsinoma kolon (C2BBE1) secara in vitro. Kulit manggis utuh segar dikeringkan, ditumbuk menjadi serbuk, dimaserasi dalam alkohol 99%, kemudian dievaporasi untuk menghasilkan crude extract kulit manggis. Dilakukan uji KLT dan fitokimia untuk mengidentifikasi kandungan ekstrak. Digunakan delapan variasi konsentrasi ekstrak, yaitu 6,2 μg/ml, 12,5 μg/ml, 25 μg/ml, 50 μg/ml, 100 μg/ml, 200 μg/ml, 400 μg/ml, dan 800 μg/ml yang dilarutkan dalam DMSO dan media RPMI sebelum ditambahkan ke sel uji. Sel uji merupakan sel adenokarsinoma kolon dari Departemen Patologi Anatomik FKUI/RSCM yang sebelum digunakan sudah ditumbuhkan, diamati pertumbuhannya, dihitung kepadatannya, dan dipelihara dalam medium kultur komplit, pada suhu 37 °C dengan kandungan 5% CO2 pada inkubator. Penambahan ekstrak dilakukan saat pertumbuhan sel konfluens dan diinkubasi kembali selama 48 jam untuk kemudian diamati di bawah mikroskop dino-eye dan dilakukan uji sitotoksisitas dengan metode MTT assay. Didapatkan nilai %inhibisi proliferasi sel dengan pemberian ekstrak berbeda bermakna terhadap kontrol dengan nilai p=0.015 (< 0,05) dengan uji Kruskal Wallis. Nilai IC50nya adalah 1,11 μg/ml yang berarti ekstrak yang mengandung polifenolat (termasuk xanton) tersebut bersifat sitotoksik kuat terhadap sel uji.

---

Colorectal cancer is the third most found cancer in Indonesia in which 95% of them are colon adenocarcinoma. Today, the therapy is still limited in resection surgey or laparoscopy which is not efficient especially in late stadium. Therefore, alternative treatments are needed to support existing therapies. One of them is Mangosteen Pericarp which is known for its many benefits including as an anticancer. In this study, mangosteen (Garcinia mangostana Linn) pericarp ethanol extract’s cytotoxicity is tested on colon adenocarcinoma cells (type C2BBE1). The fruit’s pericarp is peeled, dried, ground into powder, macerated in 99% ethanol, then evaporated to create a crude extract of mangosteen pericarp. TLC and phytocemical screening is done to detect the components of the extract. There were 8 variations of extract concentration; 6.2 μg/ml, 12,5 μg/ml, 25 μg/ml, 50 μg/ml, 100 μg/ml, 200 μg/ml, 400 μg/ml, and 800 μg/ml which were dissolved in DMSO and RPMI media before given to tested cell lines. Tested cell lines were available from anatomic pathology laboratory of FKUI RSCM which were cultured, monitored, counted, and inccubated in culture media under moist ciurcumstances (370C, 5% CO2), The extracts are given to cell lines which were 50% confluent then incubated for 48 hours. The cells then observed under microscope with dino-eye camera and tested using MTT assay kit to know the cytotoxycity. The results show significant difference between inhibition percentage of tested extracts to control with the value of p=0.015 (< 0,05) measured with Kruskal Wallis test. The IC50 value is 1.11μg/ml which means that the xanthon containing extract is highly cytotoxic to the tested cell lines."

"Kanker mulut merupakan kanker urutan ke-6 dengan insiden tertinggi di dunia. Pengobatan untuk berbagai jenis kanker termasuk kanker mulut masih sangat terbatas dan memiliki banyak efek samping sehingga perlu dicari pengobatan baru yang poten namun memiliki efek samping yang minimal. Kulit buah manggis yang sering dikonsumsi oleh masyarakat Asia Tenggara termasuk Indonesia diduga memiliki efek anti kanker karena mengandungksanton (α,β,γ mangostin). Penelitian ini bertujuan menguji efek sitotoksisitas ekstrak etanol kulit buah manggis terhadap sel kanker mulut dengan metodein vitro. Sel kanker mulut diberikan perlakuan berupa kontrol dan 8 konsentrasi (6,25μg/ml, 12,5 μg/ml, 25 μg/ml, 50 μg/ml, 100 μg/ml, 200 μg/ml, 400 μg/ml, 800 μg/ml). Pengujian secara in vitro pada sel kanker mulut yang diberi ekstrak etanol kulit buah manggis dengan dosis 6,25μg/ml - 800μg/ml dilihat viabilitas sel dibandingkan dengan kontrol. Viabilitas sel kanker diidentifikasi dengan MTT Assay kit. Setelah data didapatkan dan dianalisis menggunakan uji Kruskal-Wallis, didapatkan nilai p = 0,012 serta IC50 sebesar 4,9 μg/ml. Uji Post Hoc menunjukkan bahwa terdapat perbedaan bermakna antara kelompok kontrol dan perlakuan 6,25 μg/ml dengan kelompok lainnya.

---

Mouth cell cancer is the 6th most common cancer worldwide. The treatment for any kind of cancer including mouth cell cancer is limited and has many side effects, therefore novel and potent treatment with less side effects is needed. Pericarp of the mangosteen which is commonly consumed by Southeast Asian people including Indonesia, is suspected to have chemotherapy properties such as xanthone (α,β,γ mangosteen). This study aimed to find out the cytotoxicity level of ethanol extracts of mangosteen’s pericarp for mouth cell cancer byin vitro test. Mouth cell cancer was given eight different concentration (6.25μg/ml, 12.5 μg/ml, 25 μg/ml, 50 μg/ml, 100 μg/ml, 200 μg/ml, 400 μg/ml, 800 μg/ml) and control (medium). The viability of the mouth cell cancer was identified using MTT Assay kit. The result shows that the p value = 0.012 and the IC50 = 4.9 μg/ml using Kruskal-Wallis test. Post Hoc test show there are differences between the control and 6,25 ug/ml treatment group to the other treatment groups"

"Latar belakang: Kanker payudara adalah penyebab utama kematian akibat kanker pada wanita di seluruh dunia. Pengobatan kanker payudara saat ini sangat ditentukan reseptor hormon atau variabel klinikopatologis. Marker terkait invasi dan metastasis masih sangat dibutuhkan untuk mengembangkan biomarker baru dan strategi terapi untuk menangani kanker payudara. Diperlukan pembuktian zat bioaktif baru seperti lunasin untuk strategi yang menguntungkan terapi dan prognosis pasien kanker payudara. β-catenin adalah perantara jalur pensinyalan penting yang dapat menjadi penanda dari kanker payudara. Belum terdapat penelitian terhadap pengaruh pemberian lunasin pada ekspresi β-cateninpada kanker payudara. Metode: Penelitian ini berupa eksperimental in vivo yang dilakukan pada tikus Sprague-Dawley (SD). Terdapat 5 kelompok berbeda, semua tikus diberikan DMBA (20mg/kgBB) untuk menginduksi kanker payudara kecuali kelompok normal. (1) Kelompok (DMBA) hanya diberikan DMBA; (2) Kelompok (TAM) diberikan tamoksifen (10 mg/kgBB); (3) kelompok (ET Lun), diberikan ekstrak lunasin (500 mg/kgBB); dan (4) adjuvan, diberikan tamoksifen (10 mg/kgBB) dan ekstrak lunasin (500 mg/kgBB); (5) kelompok (NOR) tanpa DMBA dan perlakuan. Setelah terminasi, preparat histopatologi jaringan payudara sampel diberikan pewarnaan HE dan IHK. Histoscore digunakan untuk menilai tingkat ekspresi β-catenin. Setelah itu dilanjutkan dengan analisis data. Hasil: Hasil ekspresi β-catenin kelompok normal (NOR) = 138.52±8,78 ; (DMBA) = 187,30±9,70 ; Tamoxifen (TAM) = 166,14±5,60 ; Ekstrak Lunasin (ET-Lun) = 174,42±4,01 ; dan adjuvan (ADJ) = 150,65±6,44. Analisis data menunjukkan perbedaan bermakna antar kelompok kecuali antara kelompok (TAM) dengan kelo(ET Lun). Kesimpulan: Pemberian ekstrak lunasin dari kedelai dapat menurunkan ekspresi β-catenin pada jaringan kanker payudara tikus SD yang diinduksi DMBA.

---

Introduction: Breast cancer is the leading cause of cancer death in women worldwide. Current breast cancer treatment is largely determined by hormonal receptors or by clinicopathological variables. Markers related to invasion and metastasis are still urgently needed to develop new biomarkers and therapeutic strategies to treat breast cancer. Verification of new biomarkers such as lunasin is needed to create strategies that will benefit therapy and prognosis of breast cancer patients. β-catenin is an important intermediate in several important signalling pathways which can be a marker for breast cancer. To date, there is no studies about the effect of lunasin on β-catenin expression in rats with breast cancer. Method: This study is an in vivo experiment conducted on Sprague-Dawley (SD) rats. There are 5 different groups where all were given DMBA (20mg/kgBW) for breast cancer induction except for the normal group. Group (1) DMBA was given only DMBA; (2) Tamoxifen (TAM) were given DMBA and tamoxifen (10 mg/kgBW); (3) Extract Lunasin (ET-Lun), administration of lunasin extract (500 mg/kgBW); and (4) Adjuvant, were given tamoxifen (10 mg/kgBW) and lunasin extract (500 mg/kgBW). Group (5) the normal group who was not given DMBA and treatment. After termination, histopathological preparations of breast tissue were then stained with HE and IHK. The histoscore was used to assess the expression level of β-catenin. Data analysis was continued afterwards. Result: The expression of normal group -catenin (NOR) = 138.52±8.78 ; (DMBA) = 187.30±9.70 ; Tamoxifen (TAM) = 166.14±5.60 ; Ekstrak Lunasin (ET-Lun) = 174.42±4.01 ; and adjuvants (ADJ) = 150.65±6.44. Data analysis showed significant differences in all between groups except between the positive control group and the curative group. Conclusion Administration of a targeted extract of lunasin from soybeans can reduce the expression of β-catenin in breast cancer tissue of SD rats induced by DMBA."

"Terdapat sebanyak 14,1 juta kasus kanker didiagnosis dan sebanyak 8,2 juta individu meninggal setiap tahunnya dari total ±32,6 juta pengidap kanker, menurut GLOBOCAN 2012. Kanker kolorektal memberikan 9,7% dalam kasus kanker dan insidesinnya pada usia <50 tahun menjadi meningkat 13% (2000-2014). Ekspresi siklooksigenase-2 (COX-2) yang berlebihan merupakan salah satu meaknisme yang terlibat dalam patogenesis kanker kolorektal. Sayangnya, pengobatan kanker menggunakan inhibitor enxim COX, NSAID, memiliki beberapa efek samping yang prominen seperti perdarahan gastointestinal, komplikasi kardiovaskular, dan nefrotoksisitas yang diinduksi NSAID. Dalam beberapa tahun terakhir, tanaman herbal telah mengundang perhatian banyak peneliti karena mudah didapat, murah, memiliki potensi dalam pencegahan kanker, dan memiliki toksisitas yang rendah. Hal ini memicu peneliti untuk mencari apakah ekstrak etanol biji delima mampu menurunkan ekspresi COX-2 pada sel HCT116.Ektrak biji delima (Punica granatum) dimaserasi dalam etanol. Satu kelompok tidak mendapatkan perlakuan (kontrol negatif) sementara tiga kelompok lainnya diberi ekstrak ekstrak biji delima dalam tiga dosis berbeda (50, 100, dan 200 ppm). Pengaruh pemberian ekstrak etanol biji delima pada ekspresi COX-2 dalam sel HCT116 dinilai melalui perhitungan H-score dari pewarnaan imunositokimia.Ekstrak etanol biji delima (Punica granatum) menunjukkan hasil dapat menurunkan ekspresi COX-2 yang ditunjukkan melalui penurunan nilai H-score dengan rerata nilai H-score sebesar 159,07 . Dan nilai p < 0,005Penelitian ini membuktikan bahwa terjadi penurunan ekspresi protein COX-2 pada sel HCT116 setelah pemberian ekstrak etanol biji delima (Punica granatum).

---

14.1 million new cancer cases are diagnosed annually in 2012. And about 8.2 million people are dying every year worldwide while 32.6 million people are living and afflicted with cancer, according to GLOBOCAN. Colorectal cancer (CRC) contributes to 9.7% of all cancer cases and in population <50 years old its incidence increased by 13% (2000-2014). Excessive expression of COX-2 plays a role in the pathogenesis of CRC. Unfortunately, current cancer treatment using COX enzyme inhibitor, NSAIDs is known for its multiple adverse effects, including gastrointestinal bleeding, cardiovascular complications, and NSAID induced nephrotoxicity. In recent years, medicinal herbs have become popular among researchers for its easily obtainable nature, cheap, promising cancer preventing properties, and low toxicity. Thus, reseacher would like to investigate whether ethanol extract from pomegranate seed can reduce the expression of COX-2 in HCT116 cell.

Ethanol extract from pomegranate (Punica granatum) seed was prepared for maceration in ethanol. One group was given no treatment (negative control) while the other three groups were given ethanol extract from pomegranate seed in three different doses (50, 100, 200 ppm). The effect of ethanol extract of pomegranate seed on inhibition of COX-2 expression in the HCT116 cell was then assessed by counting the H-score from immunocytochemistry staining.

The ethanol pomegranate (Punica granatum) extract was shown able to decrease expression of COX-2, which was shown by decresing the H-score with average H-score 159.07. P <0,05

This study revealed there is a decrease in COX-2 protein expression in HCT116 cells after administration of ethanol pomegranate."

"Latar belakang: Penderita kanker ovarium umumnya datang berobat pada stadium lanjut, sehingga kekambuhan pasca pembedahan dan pemberian kemoterapi mencapai 70-80%. EGFR mengaktifkan jalur sinyal yang menginduksi onkogenesis dan proliferasi sel. Tujuan penelitian ini adalah untuk menganalisis peran EGFR dalam patogenesis tumor serosum ovarium dan peluangnya untuk digunakan sebagai penanda keganasan.Metode: Penelitian ini menggunakan metode potong lintang. Sampel terdiri atas 15 kasus tumor jinak, 15 kasus borderline dan 15 kasus adenokarsinoma di Departemen Patologi Anatomik FKUI/RSCM tahun 2008-2012. Dilakukan pulasan imunohistokimia EGFR dan penilaian dengan H score.Hasil: Terdapat perbedaan ekspresi EGFR yang bermakna antara kelompok tumor serosum jinak (H score = 15), borderline (H score = 60) dan adenokarsinoma (H score = 120), dengan p=0,000.Kesimpulan. Ekspresi EGFR pada tumor serosum ovarium meningkat seiring peningkatan derajat keganasan.

---

Background: Most of ovarian cancer patients are diagnosed in already advanced stage, therefore 70-80% of cases having recurrence after surgical staging and chemotherapy. EGFR activates signaling pathways which induce oncogenesis and cell proliferation. The aim of this study is to analyze the role of EGFR in the pathogenesis of serous ovarian tumors and its possibility to be used as a malignant marker.Methods: This was a cross-sectional study on each 15 cases of benign, borderline and malignant serous ovarian tumors from Anatomical Pathology Department FMUI/CMH in 2008-2012. EGFR status was assessed by immunohistochemistry technique and the expression was evaluated using H score.Results: There was significant difference between EGFR expression in benign (H score = 15), borderline (H score = 60) and malignant serous ovarian tumors (H score = 120), p=0,000.Conclusion: The EGFR immunoexpression was increased along with the higher degree of serous ovarian tumor malignancy."

"ABSTRAK Latar belakang: Endometriosis merupakan kelainan ginekologik yang palingsering ditemukan. Seperti halnya endometrium di uterus juga dapat terjadiberbagai perubahan pada epitel yang melapisi kista endometriosis di ovarium,antara lain metaplasia, hiperplasia, atipia bahkan perubahan ke arah keganasan.Saat ini banyak penelitian yang menghubungkan antara endometriosis dan kankerovarium terutama jenis clear cell dan dikenal dengan istilah endometriosisassociatedovarian carcinoma (EAOC) dan dilaporkan adanya mutasi yangmenginaktifkan gen supresor tumor (ARID1A), sehingga protein BAF250a tidakdiekpresikan pada Clear cell carcinoma (CCC) ovarii.Bahan dan cara: Dilakukan pulasan imunohistokimia ARID1A pada sampel 20kasus endometriosis non atipik, 20 kasus atipik dan 20 kasus CCC ovarii tahun2012 hingga Maret 2015. Dari kelompok kasus CCC didapatkan 9 kasus EAOC.Selanjutnya dilihat adakah perbedaan persentase ekspresi ARID1A padaendometriosis non atipik, atipik, CCC ovarii serta endometriosis disertai CCC(EAOC).Hasil: Pada kelompok kasus endometriosis non atipik, atipik dan CCC adaperbedaan bermakna persentase ekspresi ARID1A (uji Kruskal-Wallis p=0,0035).Selanjutnya dilakukan analisis Post Hoc uji Mann-Whitney dan didapatkanperbedaan bermakna persentase ekspresi ARID1A antara endometriosis non atipikdan atipik dengan CCC ovarii (p=0,001 dan p=0,0015). Pada kelompok kasusendometriosis non atipik, atipik dan endometriosis pada EAOC, didapatkan adaperbedaan bermakna persentase ekspresi ARID1A (Uji Kruskal-Walis p=0,011).Selanjutnya dilakukan analisis Post Hoc uji Mann-Whitney dan ada perbedaanbermakna persentase ekspresi ARID1A antara endometriosis non atipik dan atipikdengan EAOC (p=0,005 dan p=0,008). Kesimpulan: Ekspresi ARID1A pada endometriosis non atipik dan atipik lebihtinggi bermakna dibanding CCC ovarii dan EAOC. Sehingga ekspresi ARID1Akemungkinan dapat digunakan sebagai petanda adanya transformasi ganas padaendometriosis.ABSTRACT Background: Endometriosis is one of the most common gynecologicalabnormalities found. Endometriosis cyst in the ovary also exhibited changes inepithelial cyst just like endometrium in the uterus. Changes in the epithelial cellsalso include metaplasia, hyperplasia, atyphia even changes toward malignancharacteristics. Nowadays, there are some research that linked endometriosis andclear cell ovarian cancer which is known with endometriosis-associated ovariancarcinoma (EAOC) it is reported that there?s a mutation that activated tumorsuppressor gene (ARID1A), so protein BAF250a is not expressed in Clear CellCarcinoma (CCC) in the ovarium.Materials and Methods: Immunohistochemistry staining of ARID1A were donein 20 samples of non-atypical endometriosis, 20 samples of atypicalendometriosis, 20 samples of CCC in the ovarium from the year 2012 until march2015. From the group that experienced CCC we get 9 cases of EAOC. After that,we see if there?s any difference in the percentage of ARID1A expression in nonatypicalendometrosis, atypical endometriosis, CCC in the ovarium andendometriosis with CCC( EAOC).Results: In non-atypical endometriosis, atypical and CCC cases groups there aresignificant differences on the percentage of ARID1A expression (Kruskal-Walistest p=0,0035). Post Hoc analysis were done using Mann-Whitney test and thereare significant differences on ARID1A expression between non-atypical andatypical endometriosis with CCC (p=0,001 and p=0,0015). In non-atypicalendometriosis, atypical and EAOC groups there are significant differences on thepercentage of ARID1A expression (Kruskal-Walis test p=0,011). Post Hocanalysis were done using Mann-Whitney test and there are significant differenceson ARID1A expression between non-atypical and atypical endometriosis withEAOC (p=0,005 and p=0,008).Conclusion: Expression of ARID1A in non atypical and atypical endometriosisare significantly higher compared to ovarian CCC and EAOC. So, we can say thatARID1A may be used as a marker for malignancy transformation inendometriosis.;Background: Endometriosis is one of the most common gynecologicalabnormalities found. Endometriosis cyst in the ovary also exhibited changes inepithelial cyst just like endometrium in the uterus. Changes in the epithelial cellsalso include metaplasia, hyperplasia, atyphia even changes toward malignancharacteristics. Nowadays, there are some research that linked endometriosis andclear cell ovarian cancer which is known with endometriosis-associated ovariancarcinoma (EAOC) it is reported that there?s a mutation that activated tumorsuppressor gene (ARID1A), so protein BAF250a is not expressed in Clear CellCarcinoma (CCC) in the ovarium.Materials and Methods: Immunohistochemistry staining of ARID1A were donein 20 samples of non-atypical endometriosis, 20 samples of atypicalendometriosis, 20 samples of CCC in the ovarium from the year 2012 until march2015. From the group that experienced CCC we get 9 cases of EAOC. After that,we see if there?s any difference in the percentage of ARID1A expression in nonatypicalendometrosis, atypical endometriosis, CCC in the ovarium andendometriosis with CCC( EAOC).Results: In non-atypical endometriosis, atypical and CCC cases groups there aresignificant differences on the percentage of ARID1A expression (Kruskal-Walistest p=0,0035). Post Hoc analysis were done using Mann-Whitney test and thereare significant differences on ARID1A expression between non-atypical andatypical endometriosis with CCC (p=0,001 and p=0,0015). In non-atypicalendometriosis, atypical and EAOC groups there are significant differences on thepercentage of ARID1A expression (Kruskal-Walis test p=0,011). Post Hocanalysis were done using Mann-Whitney test and there are significant differenceson ARID1A expression between non-atypical and atypical endometriosis withEAOC (p=0,005 and p=0,008).Conclusion: Expression of ARID1A in non atypical and atypical endometriosisare significantly higher compared to ovarian CCC and EAOC. So, we can say thatARID1A may be used as a marker for malignancy transformation inendometriosis.;Background: Endometriosis is one of the most common gynecologicalabnormalities found. Endometriosis cyst in the ovary also exhibited changes inepithelial cyst just like endometrium in the uterus. Changes in the epithelial cellsalso include metaplasia, hyperplasia, atyphia even changes toward malignancharacteristics. Nowadays, there are some research that linked endometriosis andclear cell ovarian cancer which is known with endometriosis-associated ovariancarcinoma (EAOC) it is reported that there?s a mutation that activated tumorsuppressor gene (ARID1A), so protein BAF250a is not expressed in Clear CellCarcinoma (CCC) in the ovarium.Materials and Methods: Immunohistochemistry staining of ARID1A were donein 20 samples of non-atypical endometriosis, 20 samples of atypicalendometriosis, 20 samples of CCC in the ovarium from the year 2012 until march2015. From the group that experienced CCC we get 9 cases of EAOC. After that,we see if there?s any difference in the percentage of ARID1A expression in nonatypicalendometrosis, atypical endometriosis, CCC in the ovarium andendometriosis with CCC( EAOC).Results: In non-atypical endometriosis, atypical and CCC cases groups there aresignificant differences on the percentage of ARID1A expression (Kruskal-Walistest p=0,0035). Post Hoc analysis were done using Mann-Whitney test and thereare significant differences on ARID1A expression between non-atypical andatypical endometriosis with CCC (p=0,001 and p=0,0015). In non-atypicalendometriosis, atypical and EAOC groups there are significant differences on thepercentage of ARID1A expression (Kruskal-Walis test p=0,011). Post Hocanalysis were done using Mann-Whitney test and there are significant differenceson ARID1A expression between non-atypical and atypical endometriosis withEAOC (p=0,005 and p=0,008).Conclusion: Expression of ARID1A in non atypical and atypical endometriosisare significantly higher compared to ovarian CCC and EAOC. So, we can say thatARID1A may be used as a marker for malignancy transformation inendometriosis.;Background: Endometriosis is one of the most common gynecologicalabnormalities found. Endometriosis cyst in the ovary also exhibited changes inepithelial cyst just like endometrium in the uterus. Changes in the epithelial cellsalso include metaplasia, hyperplasia, atyphia even changes toward malignancharacteristics. Nowadays, there are some research that linked endometriosis andclear cell ovarian cancer which is known with endometriosis-associated ovariancarcinoma (EAOC) it is reported that there?s a mutation that activated tumorsuppressor gene (ARID1A), so protein BAF250a is not expressed in Clear CellCarcinoma (CCC) in the ovarium.Materials and Methods: Immunohistochemistry staining of ARID1A were donein 20 samples of non-atypical endometriosis, 20 samples of atypicalendometriosis, 20 samples of CCC in the ovarium from the year 2012 until march2015. From the group that experienced CCC we get 9 cases of EAOC. After that,we see if there?s any difference in the percentage of ARID1A expression in nonatypicalendometrosis, atypical endometriosis, CCC in the ovarium andendometriosis with CCC( EAOC).Results: In non-atypical endometriosis, atypical and CCC cases groups there aresignificant differences on the percentage of ARID1A expression (Kruskal-Walistest p=0,0035). Post Hoc analysis were done using Mann-Whitney test and thereare significant differences on ARID1A expression between non-atypical andatypical endometriosis with CCC (p=0,001 and p=0,0015). In non-atypicalendometriosis, atypical and EAOC groups there are significant differences on thepercentage of ARID1A expression (Kruskal-Walis test p=0,011). Post Hocanalysis were done using Mann-Whitney test and there are significant differenceson ARID1A expression between non-atypical and atypical endometriosis withEAOC (p=0,005 and p=0,008).Conclusion: Expression of ARID1A in non atypical and atypical endometriosisare significantly higher compared to ovarian CCC and EAOC. So, we can say thatARID1A may be used as a marker for malignancy transformation inendometriosis."

"Pendahuluan: Tata laksana yang tersedia untuk kanker kolorektal masih kurang efektif dan memiliki berbagai efek samping. Protein lunasin dapat mempengaruhi kanker melalui berbagai mekanisme, salah satunya epigenetik, melalui asetilasi histon. Dengan kemampuan kemopreventif dan kemoterapeutiknya, lunasin berpotensi sebagai adjuvant untuk terapi konvensional kanker.Metode: Tiga puluh mencit Swiss Webster dibagi menjadi enam kelompok, yaitu normal, kontrol positif dan negatif, dan tiga kelompok perlakuan. Selain kelompok normal, dilakukan induksi karsinogenesis dengan injeksi AOM + DSS. Mencit perlakuan diberikan ekstrak kedelai dengan dosis 250 mg/kgBB, 300 mg/kgBB, dan 350 mg/kgBB selama 4 minggu. Ekspresi histon deasetilase (HDAC) dinilai dengan IHC optical density score.Hasil: Rata-rata ekspresi HDAC pada kelompok normal = 202,4%; kontrol negatif = 239,3%; kontrol positif = 175,25%; dosis 250 mg/kgBB = 202,03%, dosis 300 mg/kgBB = 219,53%, dosis 350 mg/kgBB = 166,68%. Ekspresi HDAC pada dosis ekstrak kedelai 250 mg/kgBB (p=0,221) dan 300 mg/kgBB (p=0,347) tidak berbeda signifikan dengan kontrol negatif. Terdapat perbedaan signifikan ekspresi HDAC pada dosis sebesar 350 mg/kgBB (p=0,014).Kesimpulan: Lunasin dalam ekstrak kedelai dengan dosis 350 mg/kgBB dapat menurunkan ekspresi HDAC pada model karsinogenesis kanker kolorektal.

---

Background: The available treatments for colorectal cancer still have limited efficacy and various side effects. There are various mechanisms for lunasin protein to affect cancer, one of them is epigenetics, by histone acetylation. Lunasin has the potential to be conventional cancer therapy adjuvant with its chemopreventive and chemotherapeutic abilities.

Method: Thirty Swiss Webster mice is divided into six groups: normal, positive control, negative control, and three experimental groups. Except normal group, mice undergo carcinogenesis induction with AOM + DSS injection. Experimental mice receive soy extract with 250 mg/kgBW, 300 mg/kgBW and 350 mg/kgBW dosage for 4 weeks. Histone deacetylase (HDAC) expression is measured with IHC optical density score.

Result: Average HDAC expression on normal groups = 202,4%; negative control = 239,3%; positive control = 175,25%; 250 mg/kgBW dose = 166,68%; 300 mg/kgBW dose = 219,53%, 350 mg/kgBW dose = 166,68%. There is no significant difference between HDAC expression in 250 mg/kgBW (p=0,221) and 300 mg/kgBW (p=0,347) dose of soy extract with negative control. There is significant difference of HDAC expression with 350 mg/kgBW dose of soy extract (p=0,014).

Conclusion: Lunasin in soy extract with 350 mg/kgBW dose can decrease HDAC expression in colorectal cancer carcinogenesis model."

"ABSTRAKPendahuluan: Peradangan yang sering ditemukan pada daerah usus besar hingga rektum adalah kolitis ulserativa (UC). Pengobatan UC umumnya menggunakan kortikosteroid dan asam asetil salisilat (aspirin) yang masih efektif sebagai anti inflamasi pada kolon kiri (distal). Namun, obat ini memiliki sejumlah efek samping. Saat ini, penelitian tentang ekstrak tumbuhan herbal sebagai anti inflamasi telah berkembang. Salah satunya adalah ekstrak etanol daun mahkota dewa (Phaleria macrocarpa). Penelitian ini bertujuan untuk menganalisis pengaruh ekstrak etanol terhadap rata-rata sel goblet per kripta, jumlah fokus inflamasi, dan jumlah angiogenesis pada jaringan rektal mencit yang diinduksi Azoxymethane (AOM) dan Dextran Sodium Sulfate (DSS). Metode: Eksperimen in vivo menggunakan mencit Balb/c. Sampel penelitian ini berupa preparat histopatologi yang telah dibuat dari bahan biologis yang disimpan pada penelitian sebelumnya. Sampel dibagi menjadi 5 kelompok: normal, kontrol positif (AOM/DSS + Aspirin), kontrol negatif (AOM/DSS), EMD25 (AOM/DSS + ekstrak etanol 25%), dan EMD12.5 (AOM/DSS + 12 etanol ekstrak). ,5%). Mencit di-eutanasia kemudian diambil jaringan rektalnya, dibersihkan, dan difiksasi menggunakan buffer formalin 10%. Selanjutnya, jaringan diproses dalam blok parafin dan dilakukan pewarnaan Hematoxylin-Eosin. Hasil: Uji statistik One-way ANOVA menunjukkan bahwa rerata sel goblet per kripta, jumlah fokus inflamasi, dan jumlah angiogenesis antar kelompok tidak berbeda nyata (p>0,05). Namun, pemberian ekstrak etanol daun mahkota dewa (Phaleria macrocarpa) pada kelompok EMD25 berhasil menjaga rata-rata sel goblet per kripta mendekati kelompok normal. Kesimpulan: Ekstrak etanol daun mahkota dewa (Phaleria macrocarpa) tidak dapat menghambat inflamasi pada jaringan rektal mencit yang diinduksi OMA/DSS. Namun, ia memiliki kecenderungan untuk dapat mempertahankan rata-rata sel piala per crypt.ABSTRACTIntroduction: Inflammation that is often found in the large intestine to the rectum is ulcerative colitis (UC). Treatment of UC generally uses corticosteroids and acetyl salicylic acid (aspirin) which are still effective as anti-inflammatory agents in the left (distal) colon. However, this drug has a number of side effects. Currently, research on herbal plant extracts as anti-inflammatory has been growing. One of them is the ethanol extract of the leaves of the god crown (Phaleria macrocarpa). This study aimed to analyze the effect of ethanol extract on the goblet cell average per crypt, the number of foci of inflammation, and the amount of angiogenesis in the rectal tissue of mice induced by Azoxymethane (AOM) and Dextran Sodium Sulfate (DSS). Methods: In vivo experiments using Balb/c mice. The sample of this study was histopathological preparations that had been made from biological materials stored in previous studies. The samples were divided into 5 groups: normal, positive control (AOM/DSS + Aspirin), negative control (AOM/DSS), EMD25 (AOM/DSS + 25% ethanol extract), and EMD12.5 (AOM/DSS + 12 ethanol extract). ). ,5%). The mice were euthanized and then the rectal tissue was taken, cleaned, and fixed using 10% formalin buffer. Next, the tissue was processed in paraffin blocks and Hematoxylin-Eosin staining was performed. Results: One-way ANOVA statistical test showed that the mean of goblet cells per crypt, the number of foci of inflammation, and the number of angiogenesis between groups were not significantly different (p>0.05). However, administration of the ethanolic extract of the leaves of the god crown (Phaleria macrocarpa) in the EMD25 group managed to keep the goblet cell average per crypt close to the normal group. Conclusion: The ethanol extract of the leaves of the crown god (Phaleria macrocarpa) could not inhibit inflammation in the rectal tissue of mice induced by AOM/DSS. However, it has a tendency to be able to maintain an average of goblet cells per crypt."

"Pendahuluan: Kolitis ulserativa (UC) adalah peradangan kronis pada usus besar yang menyebabkan menyebabkan sakit perut, diare, dan perdarahan saluran cerna. Secara global, sekitar 1,2- 20,3 per seratus ribu penduduk mengalami UC. Pasien yang mengalami UC memiliki potensi Kekambuhan adalah 50% dan 20-30% di antaranya memerlukan operasi pengangkatan usus besar (kolektomi). Sampai saat ini, obat lini pertama yang digunakan untuk mengobati UC ringan sampai sedang adalah asam 5-asetil-salisilat (5-ASA). Namun, penggunaan obat-obatan Ini memiliki sejumlah efek samping seperti diare, mual, muntah dan demam. Oleh Oleh karena itu, penelitian ini ingin menguji efek anti inflamasi dari ekstrak daun mahkota dewa (Phaleria macrocarpa), yang telah lama dikenal untuk mengobati peradangan, untuk menjadi solusi alternatif untuk mengatasi UC. Metode: Sampel diperoleh dari penelitian Suprapti et al berupa preparat jaringan kolon distal mencit Balb/c yang diinduksi DSS/AOM. Selanjutnya mencit diberi ekstrak daun P. macrocarpa 25 mg dan 50 mg dengan perbandingan asetosal. Perlakuan diberikan selama 20 minggu sebelum mencit dikorbankan.Pemeriksaan histopatologi (pewarnaan hematoxylin-eosin) dilakukan dengan mengamati jumlah sel goblet, fokus inflamasi dan angiogenesis. Hasil dan Pembahasan : Ekstrak daun P. macrocarpa mampu mencegah penurunan jumlah sel goblet pada kolon distal (p<0,05) karena induksi DSS/AOM. Tidak ada penurunan yang signifikan dalam jumlah fokus peradangan (p>0,05) dan angiogenesis (p>0,05) pada kolitis setelah pemberian P. makrokarpa. Kesimpulan: Ekstrak daun P. macrocarpa mampu menghambat proses radang usus distal dengan mencegah penurunan jumlah sel goblet rata-rata,tetapi tidak mengurangi jumlah fokus peradangan atau angiogenesis.Introduction: Ulcerative colitis (UC) is a chronic inflammation of the large intestine that causes abdominal pain, diarrhea, and gastrointestinal bleeding. Globally, about 1.2-20.3 per hundred thousand people experience UC. Patients who experience UC have a recurrence potential of 50% and 20-30% of them require surgical removal of the colon (colectomy). To date, the first-line drug used to treat mild to moderate UC is 5-acetyl-salicylic acid (5-ASA). However, the use of these drugs has a number of side effects such as diarrhea, nausea, vomiting and fever. Therefore, this study wanted to test the anti-inflammatory effect of the extract of the leaves of the crown god (Phaleria macrocarpa), which has long been known to treat inflammation, to be an alternative solution to treat UC. Methods: Samples were obtained from Suprapti et al's research in the form of tissue preparations of the distal colon of Balb/c mice induced by DSS/AOM. Furthermore, the mice were given P. macrocarpa leaf extract 25 mg and 50 mg with a ratio of acetosal. The treatment was given for 20 weeks before the mice were sacrificed. Histopathological examination (hematoxylin-eosin staining) was performed by observing the number of goblet cells, foci of inflammation and angiogenesis. Results and Discussion : Leaf extract of P. macrocarpa was able to prevent the decrease in the number of goblet cells in the distal colon (p<0.05) due to DSS/AOM induction. There was no significant reduction in the number of foci of inflammation (p>0.05) and angiogenesis (p>0.05) in colitis after administration of P. macrocarpa. Conclusion: P. macrocarpa leaf extract was able to inhibit the distal intestinal inflammatory process by preventing a decrease in the average goblet cell count,but did not reduce the number of foci of inflammation or angiogenesis."